External Quality Assurance (EQA) Program for

Neonatal G6PD Screening Test



hot news 2024 External Quality Assurance (EQA) Program for Neonatal G6PD Screening Test [EQA Survey Schedule for 2024]
  Annual Summary of External Quality Assurance Survey for Neonatal G6PD Screening Test (2023)
  Application Forms Accredited to ISO/IEC 17043


G6PD EQA MIS System [login]

FAQ : [website security certificate Problem]


@@Glucose-6-phosphate dehydrogenase (G6PD; EC1.1.1.49) deficiency is the most common enzymopathic disease in Southeast Asia and other tropical areas worldwide. This X-linked genetic disorder (MIM 305900) has been found to be an important cause of neonatal jaundice and acute haemolytic anemia in the southern Chinese population in Taiwan.  In order to reduce the complications of G6PD deficiency, such as kernicterus, permanent neurological damage and death, nationwide neonatal screening for G6PD deficiency was started on 1 July 1987 after a pilot project conducted between November 1984 and June 1987 had demonstrated the practicality and the efficiency of neonatal screening of G6PD deficiency in Taiwan.  The effective collection rate has reached more than 99% of all newborns in Taiwan since 1996 and the overall incidence rate of G6PD deficiency was found to be about 2%.  To assess the reliability and to improve the quality of the screening tests performed by each neonatal screening center, an external quality assurance (EQA) program for determination for blood G6PD activity was developed since 1999.

        Periodically, 10 QC specimens were randomly picked for each survey and distributed to each neonatal screening laboratory by speed post delivery.  Reports were requested to be returned by facsimile (and internet submission since 2005) within 3 days for screening centers in Taiwan and 9 days for overseas screening centers.  For each QA survey, the G6PD activity of the QC dried blood spots was determined by quantitative assay to set the reference values before the QC specimens were send out.  The results reported by the screening centers were evaluated against the consensus result and compared with the quantitative reference values determined by our laboratory.  The summary report for each survey was published on website within two weeks after the survey started.  

Participating Laboratories

  • Austria
  • [ARCHIMED Life Science GmbH, Vienna]
  • Belgium
  • [Zentech]
  • China (Mainland)
  • [First Affiliated Hospital of Xinjiang Medical University] [Foshan Neonatal Screening Center] [Fujian Neonatal Screening Center, Fuzhou] [Guangzhou Neonatal Center] [Hunan Huaihua Maternal and Child Health Hospital] [Hunan Neonatal Screening Center][Meizhou Woman and Child Hospital Newborn Screening Center, Meizhou] [Nanning Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning] [Medical Genetics Center, Jiangmen Maternity and Child Health Care Hospital] [Qingdao Women and Children's Hospital] [Shanghai Children's Hospital] [Shanghai Neonatal Screening Center-Shanghai] [Shenzhen Neonatal Screening Center] [Xiamen's Maternal & Child Health Care Hospital] [Yang Jiang City of Guang Dong Maternal and Children's Hospital, Yangjiang] [Yueyang Maternal and Child Health Care Hospital] [Zhanjiang Neonatal Screening Center] [Zhongshan Neonatal Screening Center]

  • Finland
  • [Labsystems Diagnostics Ltd., Vantaa]
  • Germany
  • [Screening-Labor Hannover][Synlab Weiden, Weiden]
  • Greece
  • [BIOIATRIKI Group of Health, Athens] [N.DIMOPOULOS SA- RD Diagnostics, Athens]
  • India
  • [Dr Lal PathLabs, New Delhi] [Tulip Diagnostics Pvt. Ltd] [Navigene Genetic Science Pvt. Ltd.] [Sir Ganga Ram Hospital, New Delhi] [General Diagnostics International Private Limited, Navi Mumbai][Revvity Health Sciences Private Limited ( Chennai )] [Revvity Health Sciences Private Limited (Hyderabad)]
  • Mexico
  • [Ensayos y Tamizajes de Mexico, S.A. de C.V., Mexico City] [Genelab SA de CV, Mexico City] [Hospital General De Mexico Dr. Eduardo Liceaga, Mexico City] [Hospital Juarez de Mexico] [Instituto de Ciencias Medicas para la Mujer S.A. de C.V. Laboratorio ciemta] [Instituto Nacional de Perinatologia, Del. Miguel Hidalgo, Mexico City] [Tamiz Ampliado de Yucatan] [Tamizaje Plus S.A. de C.V., Merida]
  • Philippines
  • [National Institutes of Health, Manila] [Newborn Screening Center-Central Luzon, Angeles City] [Newborn Screening Center-Central Visayas, Mandaue City] [Newborn Screening Center-Mindanao, Davao City] [Newborn Screening Center-Northern Luzon, Batac City] [Newborn Screening Center-Southern Luzon, Tanauan City] [Newborn Screening Center-Visayas, Iloilo City]
  • Taiwan
  • [CFOH, Taipei] [NTU Hospital, Taipei] [TIP, Taipei]
  • Thailand
  • [Lerdsin General Hospital, Bangkok] [Queen Sirikit National Institute of Child Health, Bangkok]
  • Turkey
  • [Tanyalcin Tip Laboratory, Izmir]
  • Vietnam
  • [Genetic - Laboratory Department, Can Tho Gynecology and Obstetrics Hospital, Can Tho City] [Hanoi Hospital of Obstetrics and Gynecology - Prenatal Diagnosis and Newborn Screening Center, Hanoi] [Hue University of Medicine and Pharmacy, Hue] [Isolabo Medical Laboratory, Ho Chi Minh City] [Tu Du Hospital, Ho Chi Minh City]

    Summary Report of EQA Survey for Neonatal G6PD Screening Test :

    January 2024~

    @@@@  1. Survey No : NS2024-01

    @@@@  2. Survey No : NS2024-02


    July 1998~December 2023

    Annual Summary

    Publication Related to this G6PD EQA Program

    Announcement Related to this G6PD EQA Program



    Preventive Medicine Foundation
    Address : P.O. Box 624 Taipei Xinwei, Taiwan, 10699
    TEL : +886-2-2703-6080 ; Fax : +886-2-2703-6070
    E-mail :

    updated : 13 Jun, 2024